截至目前，西南药业对该产品累计投入研发费用 777.65 万元（未经审 计）。 重庆太极实业（集团）股份有限公司 关于葡萄糖酸钙注射液通过仿制药 一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司）控股 子公司西南药业股份有限公司（以下简称：西南药业）收到国家药品监督 管理局关于葡萄糖酸钙注射液（规格：10ml∶1g（按 C₁₂H₂₂CaO₁₄计））的《药 品补充申请批准通知书》，西南药业葡萄糖酸钙注射液通过仿制药质量和 疗效一致性评价。现将相关情况公告如下： 1 证券代码：600129 证券简称：太极集团 公告编号：2024-061 药品名称 葡萄糖酸钙注射液 剂 型 注射剂 申请事项 仿制药质量和疗效一致性评价 规 格 10ml∶1g（按C₁₂H₂₂CaO₁₄计） 注册分类 化学药品 药品注册标准编号 YBH30632024 原药品批准文号 国药准字H50020063 上市许可持有人 西南药业股份有限公司 生产企业 石家庄四药有限公司 审批结论 根据《 ...

证券代码：600129 证券简称：太极集团 公告编号：2024-060 重庆太极实业（集团）股份有限公司 关于硫酸阿托品注射液通过仿制药一致性 评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司）控股 子公司西南药业股份有限公司（以下简称：西南药业）收到国家药品监督 管理局关于硫酸阿托品注射液（规格：1ml：0.5mg）的《药品补充申请批 准通知书》，西南药业硫酸阿托品注射液通过仿制药质量和疗效一致性评 价。现将相关情况公告如下： 1 药品名称 硫酸阿托品注射液 剂 型 注射剂 申请事项 仿制药质量和疗效一致性评价 规 格 1ml：0.5mg 注册分类 化学药品 药品注册标准编号 YBH29052024 原药品批准文号 国药准字H50020044 上市许可持有人 西南药业股份有限公司 生产企业 西南药业股份有限公司 审批结论 根据《中华人民共和国药品管理法》、《国务院 关于改革药品医疗器械审评审批制度的意见》（国 发〔2015〕44 号）、《关于仿制药质量和疗效 ...

Summary of the Conference Call Record Company Information - **Company Name**: Chongqing Taiji Industrial (Group) Co., Ltd. - **Stock Code**: 600129 - **Announcement Number**: 2024-059 Key Points - The company will participate in the "Chongqing District 2024 Investor Online Collective Reception Day" event, aimed at enhancing interaction with investors [1] - The event is organized under the guidance of the Chongqing Securities Regulatory Bureau and in collaboration with the Chongqing Listed Companies Association and Shenzhen Panorama Network Co., Ltd. [1] - The event is scheduled for November 28, 2024, from 15:00 to 17:00 [1] - Investors can participate by logging into the "Panorama Roadshow" website [1] - Company executives will engage in an online communication format to address investor concerns in a "one-to-many" interaction [1] - The company encourages widespread participation from investors [1] Additional Important Information - The announcement emphasizes the company's commitment to transparency and investor relations, ensuring that the content is truthful, accurate, and complete [1]

Group 1: Event Details - The company will participate in the "Chongqing District 2024 Investor Online Collective Reception Day" event [1] - The event is scheduled for November 28, 2024, from 15:00 to 17:00 [1] - Investors can join the event via the "Panjing Roadshow" website [1] Group 2: Company Commitment - The board of directors guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The company assumes legal responsibility for the truthfulness, accuracy, and completeness of the announcement [1] Group 3: Interaction with Investors - Company executives will engage in online communication with investors in a "one-to-many" format [1] - Investors are encouraged to actively participate in the event [1]

证券代码：600129 证券简称：太极集团 公告编号：2024-058 重庆太极实业（集团）股份有限公司 关于控股子公司收到拆迁补偿款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、拆迁补偿款的基本情况 1、重庆太极实业（集团）股份有限公司（以下简称：公司）控 股子公司四川天诚药业股份有限公司（以下简称：四川天诚药业）和 绵阳太极大药房连锁有限责任公司（以下简称：绵阳太极大药房）位 于绵阳市涪城区涪城路 1 号的房产被绵阳市政府纳入了城市统一规 划改造范围。2018 年四川天诚药业和绵阳太极大药房与绵阳市涪城 区住房和城乡建设局签订了《绵阳市涪城区国有土地上房屋征收补偿 安置协议》，拆迁总价款合计 7,500 万元。 2、2021 年 1 月，四川天诚药业收到拆迁补偿款 2,000 万元，内 1 容详见公司于 2021 年 1 月 5 日披露的公告（公告编号：2021-01）。 3、2021 年 12 月，四川天诚药业收到拆迁补偿款 2,500 万元， 内容详见公司于 2021 年 12 月 31 日披露的公告（ ...

本次机构调整后公司职能部门由 18 个部门组成：总经理办公室、 行政部、党委组织部（人力资源部）、财务管理中心、证券与投资部、 审计部、法律事务部、医药研究院、数字创新中心、战略与数据运营 中心、生产管理部、安全办公室、质量监督部、工程管理中心、中药 材资源中心、商业营运管理中心、市场中心、销售中心。 特此公告。 证券代码：600129 证券简称：太极集团 公告编号：2024-057 重庆太极实业（集团）股份有限公司 关于公司组织机构调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2024 年 11 月 13 日以通讯方式召开了第十届董事会第二十四次会议，审议 通过了《关于公司组织机构调整的议案》，为进一步强化营销组织战 斗力，整合资源创新营销，加强公司产品研究与战略部署能力，提升 销售作战集群的战术穿透执行力，同意撤销营销管理中心，成立市场 中心和销售中心。 2024 年 11 月 14 日 重庆太极实业（集团）股份有限公司 ...

华福证券 a मे 太极集团（600129.SH） 业绩短期承压，人事变动落地 投资要点： 公司三季度业绩短期承压。 业绩端：2024Q1-Q3，公司实现营收 104.3 亿，同比下降 14%；实现归 母净利润 5.5 亿，同比下降 28%；实现扣非归母净利润 5 亿，同比下降 30%。 2024Q3：公司实现营收 26.2 亿，同比下降 16%；实现归母净利润 0.5 亿， 同比下降 74%；实现扣非归母净利润 0.3 亿，同比下降 79%。 分行业：2024Q1-Q3：医药工业收入为 61.9 亿，同比下降 25%；医药 商业收入为 51.1 亿，同比下降 11%；中药材资源收入为 7.2 亿，同比下降 14%；大健康及国际业务收入为 3.6 亿，同比增长 66%。 2024Q3：医药工业收入为 11.1 亿，同比下降 44%；医药商业收入为 13.7 亿，同比下降 25%；中药材资源收入为 2.3 亿。 大单品益保世灵以及藿香正气口服液表现不佳。 2024Q1-Q3：呼吸类产品 18.76 亿,同比下降 1%；消化及代谢产品 17.69 亿，同比下降 34%；抗感类产品 8.48 亿,同比下降 43%； ...

Investment Rating - The report maintains a "Buy" rating for the company [2][3]. Core Views - Short-term performance is under pressure due to multiple factors, but a return to stable growth is expected after the base disturbances are cleared [2]. - The company's revenue for the first three quarters of 2024 was 10.434 billion yuan, a decrease of 14.36%, with a net profit attributable to shareholders of 545 million yuan, down 28.10% [2]. - The report adjusts the EPS forecast for 2024-2026 to 1.11, 1.47, and 1.90 yuan respectively, down from the previous estimates of 1.72, 2.10, and 2.61 yuan [2]. Financial Performance Summary - Q3 2024 revenue was 2.617 billion yuan, a decline of 16.44%, with a net profit of 50 million yuan, down 73.82% [2]. - The pharmaceutical industrial segment reported revenue of 6.188 billion yuan, down 25.24%, with a gross margin of 61.11%, a decrease of 4.04 percentage points [2]. - The report highlights that the core product sales were below expectations due to high inventory levels and changes in sales recognition [2]. Segment Analysis - Pharmaceutical industrial revenue: 6.188 billion yuan (-25.24%), with significant declines in core products [2]. - Pharmaceutical commercial revenue: 5.109 billion yuan (-11.21%) [2]. - Traditional Chinese medicine resources revenue: 724 million yuan (-13.77%) [2]. - Health and international business revenue: 355 million yuan (+65.61%) [2]. Margin and Cost Management - Q3 2024 gross margin was 29.13%, down 16.51 percentage points year-on-year, primarily due to changes in revenue structure [2]. - The selling expense ratio decreased by 14.77 percentage points to 15.61% due to changes in accounting and proactive optimization [2]. Future Outlook - The report anticipates that product revenue and the impact of sales recognition changes will gradually clear, leading to a return to stable growth by 2025 [2]. - The management changes are expected to drive new growth opportunities [2].

Investment Rating - Buy (Maintained) [1] Core Views - The company's performance is under pressure due to multiple factors, including a high base effect and inventory issues in certain products [2] - Revenue for the first three quarters of 2024 was RMB 10.434 billion, a year-on-year decrease of 14.36%, with net profit attributable to the parent company at RMB 545 million, down 28.10% [2] - The company's pharmaceutical industrial segment saw a significant decline in sales, while the health and international segment showed strong growth [3] - The company is optimizing its marketing system, with sales expense ratio decreasing to 15.61%, down 14.76 percentage points year-on-year [3] - The company's overseas business achieved revenue of RMB 8.59 million, a year-on-year increase of 70.78% [4] - The company's core products still have significant growth potential, and the high base effect is gradually being digested [4] Financial Performance - Revenue for 2024 is expected to be RMB 13.385 billion, a year-on-year decrease of 14.32%, with net profit attributable to the parent company at RMB 609.88 million, down 25.82% [1] - Revenue for 2025 is expected to be RMB 15.138 billion, a year-on-year increase of 13.10%, with net profit attributable to the parent company at RMB 816.36 million, up 33.86% [1] - Revenue for 2026 is expected to be RMB 16.983 billion, a year-on-year increase of 12.18%, with net profit attributable to the parent company at RMB 1.0268 billion, up 25.78% [1] - The company's P/E ratio for 2024 is expected to be 23.61x, decreasing to 17.64x in 2025 and 14.03x in 2026 [1] Business Segments - Pharmaceutical industrial segment revenue for the first three quarters of 2024 was RMB 6.188 billion, down 25.24% year-on-year [3] - Pharmaceutical commercial segment revenue for the first three quarters of 2024 was RMB 5.109 billion, down 11.21% year-on-year [3] - Traditional Chinese medicine resources segment revenue for the first three quarters of 2024 was RMB 724 million, down 13.77% year-on-year [3] - Health and international segment revenue for the first three quarters of 2024 was RMB 355 million, up 65.61% year-on-year [3] Product Performance - Digestive and metabolic drugs revenue for the first three quarters of 2024 was RMB 1.769 billion, down 34.28% year-on-year [4] - Respiratory system products revenue for the first three quarters of 2024 was RMB 1.876 billion, down 1.21% year-on-year [4] - Anti-infective drugs, nervous system drugs, and cardiovascular drugs all experienced declines, mainly due to the decline in chemical drug products [4] Valuation and Forecast - The company's 2024-2026 net profit attributable to the parent company has been revised down to RMB 610 million, RMB 816 million, and RMB 1.027 billion, respectively [4] - The company's P/E valuation for 2024-2026 is 24x, 18x, and 14x, respectively [4] - The company's core products still have significant growth potential, and the high base effect is gradually being digested [4]

Investment Rating - Buy (Maintained) [1] Core Views - Short-term performance pressure due to high base effect and off-season factors, with significant declines in pharmaceutical industrial revenue [1] - New leadership changes expected to bring positive impacts, with potential for a performance turnaround [1] - Core product Huoxiang Zhengqi Oral Liquid underperformed, leading to revenue declines in key therapeutic areas [1] - Gross margin fluctuated due to structural changes, with pharmaceutical industrial gross margin dropping by 4.04pp to 61.11% [1] - Net profit margin has room for improvement, with channel inventory destocking ongoing [1] - Revenue and net profit forecasts adjusted due to underperformance of core products and external policy impacts on the chemical drug sector [1] Financial Performance Summary Revenue and Profit - 2024E revenue expected to be 12,892 million yuan, a 17% YoY decline [1] - 2024E net profit attributable to parent company expected to be 736 million yuan, a 10% YoY decline [1] - 2025E revenue forecasted at 14,242 million yuan, a 10% YoY increase [1] - 2025E net profit attributable to parent company forecasted at 867 million yuan, an 18% YoY increase [1] Key Financial Ratios - 2024E P/E ratio: 19.0, P/B ratio: 3.2 [1] - 2025E P/E ratio: 16.1, P/B ratio: 2.7 [1] - 2024E ROE: 16%, 2025E ROE: 16% [1] Segment Performance - Pharmaceutical industrial revenue in Q3 2024: 26.17 billion yuan, a 16.44% YoY decline [1] - Pharmaceutical commercial revenue in Q3 2024: 51.09 billion yuan, an 11.21% YoY decline [1] - Traditional Chinese medicine resource segment revenue in Q3 2024: 7.24 billion yuan, a 13.77% YoY decline [1] Cash Flow and Inventory - 2024E operating cash flow: 3,356 million yuan, a significant increase from 672 million yuan in 2023A [3] - Inventory turnover days in Q3 2024: 127 days, the highest in three years [1] - Accounts receivable turnover days in Q3 2024: 61 days, the highest in three years [1] Future Outlook - Revenue growth expected to rebound in 2025E and 2026E, with 10% and 11% YoY increases respectively [1] - Net profit growth expected to accelerate in 2025E and 2026E, with 18% and 16% YoY increases respectively [1] - Gross margin expected to stabilize around 47% in 2025E and 2026E [6] - Net profit margin expected to improve to 6.3% in 2025E and 6.7% in 2026E [6]